Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients.

Trial Profile

Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2013

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours; Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 03 Jul 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Feb 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 17 Jan 2012 Planned end date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top